Tracer library / [225Ac]Ac-Macropa-7065

[225Ac]Ac-Macropa-7065

Also written as [Ac-225]Macropa-7065

Radionuclide: Ac-225 t½ 14284.8 min
Modality: Therapy
Production route: —
Stage: —
Syntheses indexed: 1

Leukemia (acute and chronic)

What it is

Compound class: Antibody-chelator conjugate (radioimmunoconjugate, Macropa-PEG4 chelator on anti-aITGB2 antibody clone 7065)
Target / mechanism: Active conformation of integrin-β2 (aITGB2), a tumor-selective epitope on AML cells, targeted by conformation-specific antibody clone 7065 PMID 41282197
Clinical application: Radioimmunotherapy for Acute Myeloid Leukemia targeting aITGB2, evaluated preclinically in AML models with potential for future clinical translation PMID 41282197
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	55 ± 1.76 %	>98%	Macropa-PEG4-7065	41282197 2025 Res Sq An aliquot of 4 μL (approx. 1.11 MBq of Ac-225) was added to a vial followed by 50 μL of NH4OAc (2M, pH 5.8) and 20 μL of L-Ascorbic acid (150 mg/mL) and 120 μg of Macropa-PEG4-7065 (7.6 μL). - [225Ac]Macropa-PEG4-7065 and [225Ac]Macropa-PEG4-IgG were obtained with a radiochemical yield of 55 ± 1.76 % and 65 ± 0.06 % yield (n=4 syntheses each) with radiochemical purity exceeding 98%

Need this precursor?We can point you to suppliers for [225Ac]Ac-Macropa-7065, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41282197: 'Macropa-PEG4-7065 and Macropa-PEG4-IgG were obtained with antibody-to-chelator ratios of 1.61 and 0.43'. | Stage 28: added indication(s) onc-leukemia from consolidated missing-rubric review.